MediWound (MDWD) Competitors $18.17 +0.27 (+1.51%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$18.15 -0.02 (-0.11%) As of 10/10/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. OCS, IOVA, VIR, GHRS, AVXL, PROK, AVBP, AKBA, MRVI, and TBPHShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Oculis (OCS), Iovance Biotherapeutics (IOVA), Vir Biotechnology (VIR), GH Research (GHRS), Anavex Life Sciences (AVXL), ProKidney (PROK), ArriVent BioPharma (AVBP), Akebia Therapeutics (AKBA), Maravai LifeSciences (MRVI), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Oculis Iovance Biotherapeutics Vir Biotechnology GH Research Anavex Life Sciences ProKidney ArriVent BioPharma Akebia Therapeutics Maravai LifeSciences Theravance Biopharma MediWound (NASDAQ:MDWD) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Which has more risk and volatility, MDWD or OCS? MediWound has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Is MDWD or OCS more profitable? MediWound has a net margin of -142.18% compared to Oculis' net margin of -13,958.12%. Oculis' return on equity of -90.31% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-142.18% -96.71% -39.73% Oculis -13,958.12%-90.31%-67.85% Which has preferable earnings & valuation, MDWD or OCS? MediWound has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M9.97-$30.22M-$2.64-6.88Oculis$780K1,180.50-$97.43M-$2.67-7.90 Do institutionals and insiders have more ownership in MDWD or OCS? 46.8% of MediWound shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate MDWD or OCS? MediWound presently has a consensus target price of $32.25, indicating a potential upside of 77.49%. Oculis has a consensus target price of $41.00, indicating a potential upside of 94.40%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Oculis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer MDWD or OCS? In the previous week, Oculis had 14 more articles in the media than MediWound. MarketBeat recorded 19 mentions for Oculis and 5 mentions for MediWound. MediWound's average media sentiment score of 0.70 beat Oculis' score of 0.35 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 0 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMediWound beats Oculis on 9 of the 15 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.46M$2.65B$6.11B$10.63BDividend YieldN/A56.72%5.66%4.71%P/E Ratio-6.8822.9185.2726.57Price / Sales9.97745.20612.79132.63Price / CashN/A179.8938.5062.09Price / Book6.295.3712.726.53Net Income-$30.22M$32.78M$3.30B$275.96M7 Day Performance5.70%2.34%0.95%-0.73%1 Month Performance-4.67%8.04%6.35%3.71%1 Year Performance8.09%-1.76%80.42%37.30% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.43 of 5 stars$18.17+1.5%$32.25+77.5%+8.5%$198.46M$20.22M-6.8880News CoverageAnalyst ForecastHigh Trading VolumeOCSOculis2.8415 of 5 stars$17.54-0.5%$35.75+103.8%+40.6%$769.76MN/A-6.572Analyst ForecastIOVAIovance Biotherapeutics4.5024 of 5 stars$2.23+5.7%$11.90+433.6%-77.8%$763.51M$164.07M-1.81500News CoverageAnalyst ForecastVIRVir Biotechnology3.2973 of 5 stars$5.63+2.6%$17.30+207.3%-21.0%$762.65M$74.21M-1.41580Trending NewsInsider TradeGHRSGH Research2.9619 of 5 stars$14.53+0.6%$32.00+120.2%+72.7%$751.29MN/A-19.6310News CoveragePositive NewsAnalyst ForecastAVXLAnavex Life Sciences3.661 of 5 stars$8.65-0.1%$44.00+408.7%+81.4%$743.84MN/A-15.1840News CoverageAnalyst ForecastPROKProKidney2.9235 of 5 stars$2.48-0.4%$6.25+152.0%+77.6%$732.76M$527K-4.353Analyst ForecastAVBPArriVent BioPharma1.8944 of 5 stars$18.16+0.7%$39.14+115.5%-24.9%$731.46MN/A-4.5240Analyst ForecastAKBAAkebia Therapeutics3.4435 of 5 stars$2.71-1.1%$6.75+149.1%+114.8%$726.50M$160.18M-15.94430Positive NewsAnalyst ForecastMRVIMaravai LifeSciences3.4025 of 5 stars$2.83+0.4%$5.22+84.4%-58.2%$720.12M$259.18M-2.08610TBPHTheravance Biopharma3.1939 of 5 stars$14.43+2.6%$23.00+59.4%+73.6%$708.58M$64.38M60.13110Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Oculis Alternatives Iovance Biotherapeutics Alternatives Vir Biotechnology Alternatives GH Research Alternatives Anavex Life Sciences Alternatives ProKidney Alternatives ArriVent BioPharma Alternatives Akebia Therapeutics Alternatives Maravai LifeSciences Alternatives Theravance Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
